Findings

What do systematic reviews say?

126 questions · 127 findings · 15 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 25 · 19.7%GRADE not reported 14 · 11%Very low 22 · 17.3%Low 34 · 26.8%Moderate 31 · 24.4%High 1 · 0.8%

RISPERIDONE DEPOT vs QUETIAPINE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Mental state ‐ improvement · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.74, 0.95]
1 study · 666 participants
Moderate

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.62, 1.13]
1 study · 666 participants
Low

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.83 [1.07, 3.15]
1 study · 666 participants
Low

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 666 participants
Low

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3.07 [1.13, 8.36]
1 study · 666 participants
Low

CHLORPROMAZINE vs QUETIAPINE

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in no significant clinical response: short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.93 [0.81, 1.06]
28 studies · 3241 participants
Moderate

CHLORPROMAZINE vs QUETIAPINE

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 548 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · patients with schizophrenia

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

CHLORPROMAZINE vs QUETIAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE may leads to higher adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with QUETIAPINE (low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 8.03 [4.78, 13.51]
8 studies · 644 participants
Low

CHLORPROMAZINE vs QUETIAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.04 [0.77, 1.41]
12 studies · 1223 participants
Moderate

FLUPHENAZINE (ORAL) vs QUETIAPINE

Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.62 [0.12, 3.07]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Relapse · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Clinically important change in life skills (long term) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Quality of life (long term) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs QUETIAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.46 [0.05, 4.46]
1 study · 25 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Cost‐effectiveness · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

COMPARISON 1. ARIPIPRAZOLE vs QUETIAPINE

Leaving the study early · patients with schizophrenia

It is very uncertain whether COMPARISON 2. ARIPIPRAZOLE changes leaving the study early compared with QUETIAPINE (very low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.8 [0.22, 2.87]
2 studies · 168 participants
Very low